In this regard, the Italian Expanded Access Program (EAP) of nivolumab in NSCLC represented an important opportunity to test our hypothesis, and we started an exploratory analysis evaluating the T19007C and C8092A ERCC-1 gene polymorphisms from two independent cohorts of patients enrolled in this study. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.